Dashboard PDUFA PDUFA History Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free public preview Track BHVN with free AI briefings, catalyst countdowns, and dilution alerts.

BHVN — Biohaven Ltd.

FDA catalysts, PDUFA dates with approval probability, drug pipeline, cash runway and insider activity — updated automatically from SEC, FDA and ClinicalTrials.gov data.

$273.1M Cash on Hand

5.8mo Cash Runway

21.5% Short Interest

🧪 Upcoming Trial Catalysts

2026-09-01 · Phase 2 — Active Trial — Taldefgrobep Alfa in Adults With Overweight and Obesity
2026-09-01 · Phase 1 — Recruiting — Study of BHV-1300 in Graves' Disease
2026-11-01 · Phase 1 — Enrolling — A Phase 1b Study of BHV-7000 in Participants With Inherited Erythromelalgia
2026-12-01 · Phase 2, Phase 3 — Recruiting — A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Ons
2026-12-01 · Phase 2 — Enrolling — Long-term Safety and Tolerability of BHV-7000
2027-07-01 · Phase 1 — Recruiting — Study of BHV-1400 in IgA Nephropathy

📊 Drug Pipeline

Drug	Indication	Phase	Status
Verdiperstat	Multiple System Atrophy	PHASE3	COMPLETED
Troriluzole (BHV-4157)	Obsessive Compulsive Disorder	PHASE3	TERMINATED
BHV-1400	IgA Nephropathy	PHASE3	NOT_YET_RECRUITING
Troriluzole	Spinocerebellar Ataxias	PHASE3	ACTIVE_NOT_RECRUITING
ADI-PEG 20	Glioblastoma	PHASE2	RECRUITING
VT1021	Glioblastoma	PHASE2	RECRUITING
VAL-083	Glioblastoma	PHASE2	RECRUITING
Tinostamustine	Glioblastoma	PHASE2	RECRUITING
Temozolomide	Glioblastoma	PHASE2	RECRUITING
taldefgrobep alfa	Obesity	PHASE2	ACTIVE_NOT_RECRUITING

💰 Cash Runway & Dilution Risk

BHVN holds $273.1M in cash and burns about $140.3M/quarter from operations, giving an estimated runway of 5.8 months. A recent offering filing was detected — dilution watch.

Source: SEC EDGAR XBRL (operating cash flow). Get dilution alerts for BHVN free →

📈 Recent Insider Activity (Form 4)

Date	Insider	Type	Value
2026-04-30	CHILDS JOHN W	Purchase	$0
2026-04-30	GREGORY JULIA P	Purchase	$0
2026-04-30	HUGIN ROBERT J	Purchase	$0
2026-04-30	Bailey Gregory	Purchase	$0
2026-04-30	Heffernan Michael Thomas	Purchase	$0

📅 Past FDA Decisions & Stock Reactions

Date	Drug	Type	Run-up 30d	Decision 1d	After 5d
2025-05-14	Rare Disease	NDA	+10.7%	+0.8%	-16.7%

Browse all historical PDUFA outcomes →

Get the full BHVN picture

A free BioRadar account adds AI daily briefings, sentiment tracking, trial enrollment progress, and email alerts for BHVN and 2 more tickers of your choice.

Create Free Account →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z